falsefalse

ELCC Updates in Immunotherapy and Beyond for Non–Small Cell Lung Cancer - Episode 10

The Evolution of Chemoimmunotherapy in Advanced NSCLC

, ,

Closing their discussion, the panel shares their final thoughts on recent updates in advanced NSCLC and looks to the future of treatment.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Overview of PD-L1 Testing in Advanced NSCLC
    EP. 2: Subgrouping Patients with Advanced NSCLC for Tailored Treatment
    EP. 3: CTLA-4 Targeted Regimens in Advanced NSCLC
    EP. 4: Updates in Gender-Based Treatment for Patients with Advanced NSCLC
    EP. 5: Data Updates on Single-Agent Immunotherapy in Advanced NSCLC
    EP. 6: Updates from ELCC: Efficacy of Frontline Nivolumab + Ipilimumab in Metastatic Non-Squamous NSCLC
    EP. 7: Updates from ELCC: 5-Year Update on Pembrolizumab vs Chemotherapy in Advanced NSCLC
    EP. 8: Updates from ELCC: Advanced NSCLC and the EMPOWER-Lung1 Trial
    EP. 9: Combination Chemotherapy and Immunotherapy for Advanced NSCLC
    Now Viewing
    EP. 10: The Evolution of Chemoimmunotherapy in Advanced NSCLC

    Sponsored in part by Regeneron. Content independently created by OncLive.

    Related Content:

    ELCC Updates in Immunotherapy and Beyond for Non–Small Cell Lung CancerLung CancerImmunotherapy in Lung CancerOncLive Peer Exchange®
    Less Is More With Advanced Surgical Approaches in Early-Stage NSCLC
    Key Takeaways From Iopofosine I 131 in Previously Treated Patients With Waldenstrom Macroglobulinemia (WM) in the CLOVER-WaM Trial
    Overview of the 5-Year Follow-Up Analysis From ZUMA-5: A Phase 2 Trial of Axi-Cel in R/R Indolent NHL
    x